FinancialNewsletterPress releases

Q2 Interim Report October – December 2025

Hamlet Biopharma

|

February 13, 2026

Related Documents

HBP_Q2_2025_EN_260213.pdf

Recent posts

Pressrelease – Lund, 15 mars 2026 – Styrelsen beslutar om justering av villkoren för teckningsoptioner av serie TO5B och inför ny kompletterande teckningsperiod 16-23 mars 2026

March 15, 2026

Nyhetsbrev – Hamlet BioPharma har undertecknat ett Letter of Intent avseende ett potentiellt kommersiellt avtal avseende Alpha 1H

March 9, 2026

PRESS RELEASE – Lund, March 8, 2026 – Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H

March 8, 2026

Nyhetsbrev – Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner

February 23, 2026

PRESS RELEASE – Lund, February 12th, 2026 – Nature Microbiology publishes the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’

Newsletter – Catharina Svanborg featured in Global Digital Women’s Magazine

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive
Pressreleases and Newsletters

© 2026

Hamlet BioPharma.